Medite Cancer Diagnostics, Inc.
MDIT
$0.00
$0.000.00%
| 09/30/2018 | 06/30/2018 | ||||
|---|---|---|---|---|---|
| Revenue | 5.23% | 51.16% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.23% | 51.16% | |||
| Cost of Revenue | -23.87% | 3.85% | |||
| Gross Profit | 38.58% | 216.42% | |||
| SG&A Expenses | 78.48% | -17.08% | |||
| Depreciation & Amortization | -8.82% | -4.23% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.08% | -6.57% | |||
| Operating Income | -239.29% | 97.08% | |||
| Income Before Tax | -31.48% | 60.13% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -30.55% | 59.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -30.55% | 59.84% | |||
| EBIT | -239.29% | 97.08% | |||
| EBITDA | -182.50% | 104.50% | |||
| EPS Basic | 0.94% | 70.88% | |||
| Normalized Basic EPS | 0.00% | 71.88% | |||
| EPS Diluted | 0.94% | 70.88% | |||
| Normalized Diluted EPS | 0.00% | 71.88% | |||
| Average Basic Shares Outstanding | 30.47% | 41.58% | |||
| Average Diluted Shares Outstanding | 30.47% | 41.58% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
